Kinn Therapeutics

What Kinn Therapeutics does

KinN Therapeutics AS is a Bergen, Norway-based preclinical contract research organization operating in the oncology drug development value chain. The company provides specialized in vivo and in vitro preclinical services for pharmaceutical and biotechnology companies developing novel anticancer compounds, with its service portfolio anchored on xenograft cancer models including both Cell Line Derived Xenograft (CDX) and Patient Derived Xenograft (PDX) material, supporting both subcutaneous and orthotopic implantation approaches. Complementary offerings encompass multimodal imaging services (near-infrared fluorescence imaging, bioluminescent imaging, and CD24-targeted fluorescence image-guided surgery for ovarian carcinoma), bioassays, theranostics development, and custom model development with a specialized spotlight on Acute Myeloid Leukemia (AML). The firm derives revenue from professional-services contracts with pharma and biotech clients, delivered via direct enterprise scientific engagement and tailored experimental design, supported by an AAALAC-accredited animal facility operating under Norwegian Food Safety Authority and EU Directive 2010/63/EU compliance.

Name

Kinn Therapeutics

Legal name

KinN Therapeutics AS

Website

https://kinntherapeutics.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

KinN Therapeutics AS is a Bergen, Norway-based preclinical contract research organization providing xenograft cancer models (CDX and PDX), orthotopic implantation, fluorescence imaging, bioassays, and AML-focused services to pharma and biotech companies developing novel anticancer compounds.

Ownership category

akta.pro rank

Product category

Preclinical Oncology Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Formulation & Preclinical CMC Support (Nonclinical) (HLAGAFAL)

akta.pro secondary industry

Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)

Keywords

• Preclinical oncology services
• Xenograft cancer models
• Preclinical drug development
• Cancer imaging services
• Biopharmaceutical research services

Headquarters

HQ city

Bergen

HQ country

Norway

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Preclinical Oncology Services: Contract research services for pharmaceutical and biotech companies developing anticancer compounds, including preclinical studies, model development, and experimental design.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Kinn Therapeutics provides tailored preclinical oncology services for pharmaceutical and biotech companies developing novel anticancer compounds. The company's core work centers on xenograft cancer models (CDX and PDX) with subcutaneous and orthotopic implantation, supported by in vivo and in vitro assessment methods, multimodal imaging (near-infrared fluorescence and bioluminescent), bioassays, theranostics, and custom model development. Services are delivered through personalized, scientist-to-scientist engagement with custom experimental design to support clients in progressing anticancer drug candidates toward clinical trials.

Product overview

Kinn Therapeutics is a biopharmaceutical services company offering a unified preclinical oncology service platform centered on xenograft cancer models. The core offering is Preclinical Oncology Services, supported by complementary modules including Xenograft Models (CDX and PDX), Imaging Services, Bioassays, Theranostics, Custom Model Development, and Tailored Experimental Design. The company also maintains a specialized focus on Acute Myeloid Leukemia (AML) through its AML Spotlight offering. Services are delivered through personalized approach with direct scientist communication, in vivo and in vitro assessment methods, and orthotopic implantation capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Preclinical Oncology Services Comprehensive preclinical oncology service offering for pharmaceutical and biotech companies developing novel anticancer compounds, providing tailored experimental design and direct scientist collaboration to progress drug candidates toward clinical trials.
• Xenograft Models Cancer models using xenograft approaches including CDX (Cell Line Derived Xenograft) and PDX (Patient Derived Xenograft) material, with capability for both orthotopic and subcutaneous implantation to track cancer progression over time.
• Imaging Services Multimodal imaging services for monitoring treatment response and tumor progression in preclinical models, including near-infrared fluorescence imaging and bioluminescent imaging.
• Bioassays In vitro assay services for assessing drug treatment effectiveness across various cancer types.
• Theranostics Integrated diagnostic and therapeutic services combining imaging probes with targeted treatment approaches for oncology research.
• Custom Model Development Bespoke development of CDX and PDX models tailored to specific research requirements and disease pathologies.
• Tailored Experimental Design Customized experimental planning and design services working directly with clients to meet specific preclinical study needs.
• AML Spotlight Specialized focus on Acute Myeloid Leukemia (AML) models and research services.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core.

• EXACT-TxcoreStrategic or Co-development PartnerStrategic partner working on translating oncology treatments from laboratory research to clinical trials.
• Celgene (BMS-Celgene)coreStrategic or Co-development PartnerCollaboration with Celgene (now part of Bristol-Myers Squibb) for oncology research translation.
• Inven2coreStrategic or Co-development PartnerNational partner in Norway for translating oncology treatments to clinical applications.
• Nordic NanovectorcoreStrategic or Co-development PartnerCollaboration with Nordic Nanovector on oncology theranostics development.
• DCprimecoreStrategic or Co-development PartnerPartnership with DCprime for cancer immunotherapy research.
• ImmunicumcoreStrategic or Co-development PartnerCollaboration with Immunicum on oncology treatment development.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Regional players

• Bioneer A/S: Danish preclinical CRO providing in vivo pharmacology services including cancer models and xenograft studies, comparable in scale and Nordic-European geographic focus.

Broad incumbents

• WuXi AppTec: Global CRO/CDMO offering preclinical oncology services including xenograft models and in vivo pharmacology at scale, with broader drug discovery and development capabilities.
• Inotiv: Contract research organization providing preclinical services including toxicology, pharmacology, and animal model services with oncology applications.
• Charles River Laboratories: Largest global preclinical CRO offering oncology services including xenograft models, imaging, and biosafety testing as part of a broad portfolio spanning discovery, safety assessment, and manufacturing.
• Horizon Discovery (Revvity): Provides cell line engineering, in vivo services, and preclinical oncology models including CRISPR-modified xenograft models as part of broader life sciences tools portfolio.

Direct peers

• The Jackson Laboratory: Non-profit biomedical research institution with significant preclinical oncology services including PDX model development, in vivo pharmacology, and tumor biology studies.
• Crown Bioscience: Global preclinical oncology CRO specializing in xenograft models (CDX, PDX), in vivo imaging, and immuno-oncology services, directly competing with Kinn's core service offerings.
• EPL Bio Analytical Services: Preclinical CRO offering in vivo pharmacology services including oncology efficacy studies and xenograft models for biotech and pharma sponsors.
• Oncodesign: European preclinical CRO with significant oncology focus offering in vivo pharmacology, translational services, and proprietary patient-derived xenograft models.
• MI Bioresearch: Preclinical CRO specializing in syngeneic, xenograft, and humanized mouse tumor models for oncology efficacy studies, closely matching Kinn's CDX/PDX service profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kinn-therapeutics-as

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kinn Therapeutics